Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02088541 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Selinexor
DRUG: Hydroxyurea
DRUG: Ara-C

Sponsor

Karyopharm Therapeutics Inc